Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Ovarian Neoplasms

  Free Subscription


15.06.2020

1 Cancer Chemother Pharmacol
8 Gynecol Oncol
2 Hum Pathol
1 Int J Gynecol Pathol
1 J Natl Cancer Inst
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Cancer Chemother Pharmacol

  1. ZHU Y, Liu Z, Qu Y, Zeng J, et al
    YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
    Cancer Chemother Pharmacol. 2020 Jun 9. pii: 10.1007/s00280-020-04098.
    PubMed         Abstract available


    Gynecol Oncol

  2. CHAMBERS LM, Pendlebury A, Rose PG, Yao M, et al
    Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2020 Jun 1. pii: S0090-8258(20)31018.
    PubMed         Abstract available

  3. ARMEL SR, Volenik A, Demsky R, Malcolmson J, et al
    Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing.
    Gynecol Oncol. 2020 Jun 3. pii: S0090-8258(20)31082.
    PubMed         Abstract available

  4. BOLAND JL, Zhou Q, Iasonos AE, O'Cearbhaill RE, et al
    Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy.
    Gynecol Oncol. 2020 Jun 2. pii: S0090-8258(20)31073.
    PubMed         Abstract available

  5. HAMILTON E, O'Malley DM, O'Cearbhaill R, Cristea M, et al
    Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
    Gynecol Oncol. 2020 Jun 5. pii: S0090-8258(20)31123.
    PubMed         Abstract available

  6. STRAUBHAR AM, Filippova OT, Cowan RA, Lakhman Y, et al
    A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31126.
    PubMed         Abstract available

  7. BOGANI G, Lopez S, Mantiero M, Ducceschi M, et al
    Immunotherapy for platinum-resistant ovarian cancer.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31924.
    PubMed         Abstract available

  8. NARASIMHULU DM, McGree ME, Weaver AL, Jatoi A, et al
    Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31131.
    PubMed         Abstract available

  9. ROCHE KL, Chi DS
    Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward...or too much risk?
    Gynecol Oncol. 2020;157:561-562.
    PubMed        


    Hum Pathol

  10. NOOR M, Chen A, Gonzalez RS
    Gynecologic proliferations of the appendix.
    Hum Pathol. 2019 Aug 17. pii: S0046-8177(19)30137.
    PubMed         Abstract available

  11. ZHOUCHUNYANG X, Cochrane DR, Tessier-Coutier B, Leung S, et al
    Expression of L1 retrotransposon open reading frame protein 1 (L1ORF1p) in gynecologic cancers.
    Hum Pathol. 2019 Jun 17. pii: S0046-8177(19)30103.
    PubMed         Abstract available


    Int J Gynecol Pathol

  12. CHIESA-VOTTERO A
    Risk of Malignancy in Postmenopausal Patients With Ovarian Torsion.
    Int J Gynecol Pathol. 2020;39:e4.
    PubMed        


    J Natl Cancer Inst

  13. LI N, McInerny S, Zethoven M, Cheasley D, et al
    Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.
    J Natl Cancer Inst. 2019 Apr 5. pii: 5428180. doi: 10.1093.
    PubMed         Abstract available


    PLoS One

  14. PRICE JC, Azizi E, Naiche LA, Parvani JG, et al
    Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.
    PLoS One. 2020;15:e0233962.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: